, Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study, N Engl J Med, vol.321, pp.129-164, 1989.

P. M. Ridker, N. R. Cook, and I. Lee, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, N Engl J Med, vol.352, pp.1293-304, 2005.

J. M. Guirguis-blake, C. V. Evans, C. A. Senger, E. A. O'connor, and E. P. Whitlock, Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force, Ann Intern Med, vol.164, pp.804-817, 2016.

P. M. Rothwell, M. Wilson, and C. E. Elwin, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, vol.376, pp.1741-50, 2010.

, The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med, vol.379, pp.1529-1568, 2018.

J. M. Gaziano, C. Brotons, and R. Coppolecchia, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, doubleblind, placebo-controlled trial, Lancet, 2018.

J. J. Mcneil, R. L. Woods, and M. R. Nelson, Effect of aspirin on disability-free survival in the healthy elderly, N Engl J Med, vol.379, pp.1499-508, 2018.

J. J. Mcneil, R. Wolfe, and R. L. Woods, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med, vol.379, pp.1509-1527, 2018.

J. J. Mcneil, M. R. Nelson, and R. L. Woods, Effect of aspirin on all-cause mortality in the healthy elderly, N Engl J Med, vol.379, pp.1519-1547, 2018.

R. Collins, C. Reith, and J. Emberson, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, vol.388, pp.2532-61, 2016.

. Copyright, Massachusetts Medical Society, 2018.

, Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study, N Engl J Med, vol.321, pp.129-164, 1989.

P. M. Ridker, N. R. Cook, and I. Lee, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, N Engl J Med, vol.352, pp.1293-304, 2005.

J. M. Guirguis-blake, C. V. Evans, C. A. Senger, E. A. O'connor, and E. P. Whitlock, Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force, Ann Intern Med, vol.164, pp.804-817, 2016.

P. M. Rothwell, M. Wilson, and C. E. Elwin, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, vol.376, pp.1741-50, 2010.

, The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med, vol.379, pp.1529-1568, 2018.

J. M. Gaziano, C. Brotons, and R. Coppolecchia, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, doubleblind, placebo-controlled trial, Lancet, 2018.

J. J. Mcneil, R. L. Woods, and M. R. Nelson, Effect of aspirin on disability-free survival in the healthy elderly, N Engl J Med, vol.379, pp.1499-508, 2018.

J. J. Mcneil, R. Wolfe, and R. L. Woods, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med, vol.379, pp.1509-1527, 2018.

J. J. Mcneil, M. R. Nelson, and R. L. Woods, Effect of aspirin on all-cause mortality in the healthy elderly, N Engl J Med, vol.379, pp.1519-1547, 2018.

R. Collins, C. Reith, and J. Emberson, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, vol.388, pp.2532-61, 2016.

, Dans l'attente d'un changement possible dans les directives nationales françaises (HAS et certaines sociétés savantes)

, Ministère des Solidarités et de la Santé, Recommandations de bonne pratique-Bon usage des agents antiplaquettaires-Argumentaire-Haute Autorité de santé 2012, 2016.

. Le-risque-cardiovasculaire and . Score,

, Haute Autorité de Santé -Évaluation et prise en charge du risque

C. Rolland and F. Sicot, Les recommandations de bonne pratique en santé. Gouv Action Publique, vol.3, pp.53-75, 2012.

. Gaucherfrance, Tout savoir sur l'Autorisation de Mise sur le Marché d'un médicament

G. France, , 2016.

, Haute Autorité de Santé -Traitement médicamenteux du diabète de type 2 : recommandation retirée le 2 mai, 2011.

M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons et al., , 2016.

, European Guidelines on cardiovascular disease prevention in clinical practiceThe Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, Eur Heart J. 1 août, vol.37, issue.29, pp.2315-81, 2016.

M. Geoffroy-plasqui, F. Raineri, P. Arnould, and G. Hebbrecht, La prescription hors autorisation de mise sur le marché en médecine générale, 2012.

, Prescription hors AMM | Conseil départemental du Val de Marne de l'Ordre des médecins, ROSP : à quand des critères utiles à la santé des patients diabétiques et à la santé publique, 2015.

A. D. Bell, A. Roussin, R. Cartier, W. S. Chan, J. D. Douketis et al., The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary, Can J Cardiol. 1 mars, vol.27, issue.2, pp.208-229, 2011.

Y. Ikeda, K. Shimada, T. Teramoto, S. Uchiyama, T. Yamazaki et al., Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors: A Randomized Clinical Trial, JAMA.17 déc, vol.312, issue.23, pp.2510-2530, 2014.

, Primary and Secondary Prevention of Cardiovascular Disease -CHEST

E. P. Whitlock, B. U. Burda, S. B. Williams, J. M. Guirguis-blake, and C. V. Evans, Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force, Ann Intern Med 21 juin, vol.164, issue.12, p.826, 2016.

, Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes | Circulation

A. L. Francke, M. Smit, A. De-veer, and P. Mistaen, Factors influencing the implementation of clinical guidelines for health care professionals: A systematic meta-review, BMC Medical Informatics and Decision Making, vol.8, p.38, 2008.

J. Carthey, S. Walker, V. Deelchand, C. Vincent, and W. H. Griffiths, Breaking the rules: understanding non-compliance with policies and guidelines, BMJ, vol.343, p.5283, 2011.

R. Peto, R. Gray, R. Collins, K. Wheatley, C. Hennekens et al., Randomised trial of prophylactic daily aspirin in British male doctors, Br Med J Clin Res Ed. 30 janv, vol.296, issue.6618, pp.313-319, 1988.

, Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk -The Lancet

P. M. Ridker, N. R. Cook, I. Lee, D. Gordon, J. M. Gaziano et al., A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women, N Engl J Med. 31 mars, vol.352, issue.13, pp.1293-304, 2005.

, Hypertension Optimal Treatment (HOT) trial -The Lancet

G. De-gaetano, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project, Lancet Lond Engl. 13 janv, vol.357, issue.9250, pp.89-95, 2001.

J. Belch, A. Maccuish, I. Campbell, S. Cobbe, R. Taylor et al., The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, BMJ, vol.337, p.1840, 2008.

. Low-dose, Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial, | Endocrinology | JAMA | JAMA Network

L. Bowman, M. Mafham, W. Stevens, R. Haynes, T. Aung et al., ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes, Am Heart J. 1 avr, vol.198, pp.135-179, 2018.

A. Kassoff, S. M. Buzney, J. W. Mcmeel, J. J. Weiter, G. J. Doyle et al., Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report 14, JAMA, vol.9, issue.10, pp.1292-300, 1992.

R. S. Eidelman, P. R. Hebert, S. M. Weisman, and C. H. Hennekens, An update on aspirin in the primary prevention of cardiovascular disease, Arch Intern Med. 22 sept, vol.163, issue.17, pp.2006-2016, 2003.

J. S. Berger, M. C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni et al., Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Metaanalysis of Randomized Controlled Trials, JAMA. 18 janv, vol.295, issue.3, pp.306-319, 2006.

, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet, Collaboration AT (ATT), vol.373, pp.1849-60, 2009.

, Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial. | Anticoagulation | JAMA | JAMA Network

P. Sutcliffe, M. Connock, T. Gurung, K. Freeman, S. Johnson et al.,

, Aspirin in Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Review of the Balance of Evidence from Reviews of Randomized Trials, PLoS ONE. 5 déc, vol.8, issue.12, 2013.

C. Patrono, Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?, Eur Heart J, vol.34, issue.44, pp.3403-3414, 2013.

N. Raju, M. Sobieraj-teague, J. Hirsh, O. Donnell, M. Eikelboom et al., Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease, Am J Med. 1 juill, vol.124, issue.7, pp.621-630, 2011.

, Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?, European Heart Journal | Oxford Academic

M. Pignone, M. J. Alberts, J. A. Colwell, M. Cushman, S. E. Inzucchi et al., Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes, J Am Coll Cardiol juin, vol.55, issue.25, pp.2878-86, 2010.

S. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, S. Erqou et al., Effect of Aspirin on Vascular and Nonvascular Outcomes: Meta-analysis of Randomized Controlled Trials, Arch Intern Med 13 févr, vol.172, issue.3, pp.209-225, 2012.

A. A. Bartolucci and G. Howard, Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using Aspirin, Am J Cardiol. 15 sept, vol.98, issue.6, pp.746-50, 2006.

J. S. Berger, A. Lala, M. J. Krantz, G. S. Baker, and W. R. Hiatt, Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials, Am Heart J.1 juill, vol.162, issue.1, pp.115-124, 2011.

S. Halvorsen, F. Andreotti, J. M. Berg, M. Cattaneo, S. Coccheri et al., Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position Paper of the European Society of Cardiology Working Group on Thrombosis, J Am Coll Cardiol. 22 juill, vol.64, issue.3, pp.319-346, 2014.

, Aspirin for primary prevention of cardiovascular events in people with diabetes: metaanalysis of randomised controlled trials | The BMJ

C. Zhang, A. Sun, P. Zhang, C. Wu, S. Zhang et al., Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis, Diabetes Res Clin Pract. 1 févr, vol.87, issue.2, pp.211-219, 2010.

, Aspirin for the Primary Prevention of Cardiovascular Events | Diabetes Care

F. Matthys, D. Backer, T. , D. Backer, G. Stichele et al., Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?, Eur J Prev Cardiol 1 mars, vol.21, issue.3, pp.354-65, 2014.

, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials -The Lancet

, Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials -The American Journal of Medicine

P. M. Rothwell, J. F. Price, F. Fowkes, A. Zanchetti, M. C. Roncaglioni et al., Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet 28 avr, vol.379, pp.1602-1614, 2012.

J. J. Mcneil, R. L. Woods, M. R. Nelson, C. M. Reid, B. Kirpach et al., Effect of Aspirin on Disability-free Survival in the Healthy Elderly, N Engl J Med, vol.379, issue.16, pp.1499-508, 2018.

J. M. Gaziano, C. Brotons, R. Coppolecchia, C. Cricelli, H. Darius et al., Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, The Lancet. sept, vol.392, pp.1036-1082, 2018.

, Validation comparée d'un nouveau score de risque pour la prédiction du risque de saignement chez les patients anticoagulés présentant une fibrillation auriculaire: l'indice HAS-BLED (hypertension, fonction rénale / hépatique anormale, accident vasculaire cérébral, saignement ou prédisposition, Labile INR, personne âgée, Drogues / alcool concomitant) ScienceDirect

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer leurs consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses : que je sois déshonoré(e) et méprisé(e) si j'y manque

, heterogeneity of practices about habits and prescription criteria underlines the notion of a brain teaser in clinical practice; all reflecting a lack of clarity of the current recommendations and conclusions of learned societies, often contradictory

, Conclusion: There are real difficulties in prescribing AAS for primary prevention of cardiovascular events for general practitioners in Reunion. The current data of science do not make it possible to maintain its prescription in this context because of non-favorable benefit-risk ratio. KEY WORDS: aspirin